"10.1371_journal.pone.0059767","plos one","2013-03-29T00:00:00Z","Camille L√©curoux; Isabelle Girault; Antoine Ch√©ret; Pierre Versmisse; Georges Nembot; Laurence Meyer; Christine Rouzioux; Gianfranco Pancino; Alain Venet; Asier S√°ez-Ciri√≥n; ANRS 147 OPTIPRIM clinical trial","INSERM, U1012, Le Kremlin Bic√™tre, France; H√¥pital Gustave Dron, Service de Maladies Infectieuses et du voyageur, Tourcoing, France; EA 3620, Universit√© Paris-Descartes, Sorbonne Paris Cit√©, Paris, France; Institut Pasteur, Unit√© de R√©gulation des Infections R√©trovirales, Paris, France; INSERM U1018, Universit√© Paris-Sud 11, Le Kremlin Bic√™tre, France; AP-HP, H√¥pital de Bic√™tre, D√©partement d‚Äô√©pid√©miologie, Le Kremlin Bic√™tre, France; AP-HP, CHU Necker-Enfants Malades, Laboratoire de Virologie, Paris, France","Critical reviewing of manuscript: CL IG AC PV GN LM CR GP AV AS-C. Conceived and designed the experiments: AC CR GP AV AS-C. Performed the experiments: CL IG PV. Analyzed the data: CL IG LM GP AV AS-C. Contributed reagents/materials/analysis tools: GN. Wrote the paper: CL AS-C.","The OPTIPRIM clinical trial was funded by the ANRS (French National Agency for Research on AIDS and Viral Hepatitis). However, ANRS received financial support from MSD, Janssen, ViiV Healthcare and Gilead to complement funding concerning this trial. This does not alter the authors‚Äô adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Camille L√©curoux","CL√",11,TRUE,5,3,6,2,TRUE,TRUE,FALSE,0,NA,FALSE
